Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)

Summary

Currently, there are no licensed therapeutics against Zika virus infection. Due to this unmet medical need, Zika Virus Immune Globulin (ZIKV-IG) is being developed as a therapeutic intervention against Zika virus infection. In this first-in-human study, evaluation of ZIKV-IG safety and pharmacokinetics (absorption, metabolism and excretion) will be conducted in healthy adult volunteers.

Timeline

Start

2018-06-27

Primary completion

2019-03-06

Completion

2019-03-06

Publications

• White J, Tunga P, Anderson DM, Iledan K, Loreth T, Parrera GS, Astacio H, Drobic B, Richardson JS. Results of a Double-Blind, Randomized, Placebo-Controlled Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Anti-Zika Virus Immunoglobulin. Am J Trop Med Hyg. 2021 Oct 4;105(6):1552-1562. doi: 10.4269/ajtmh.20-1578.

Drugs

Indications